Vo, Ashley A <br/><br/>
Rituximab and intravenous immune globulin for desensitization during renal transplantation.  [electronic resource] 

 -  The New England journal of medicine  Jul 2008 
 - 242-51 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1533-4406 
<br/><br/><label>Standard No.: </label>10.1056/NEJMoa0707894  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies--blood<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antigens, CD19--blood<br/>Antigens, CD20--immunology<br/>Creatinine--blood<br/>Desensitization, Immunologic--methods<br/>Drug Therapy, Combination<br/>Female<br/>Graft Rejection--epidemiology<br/>HLA Antigens--immunology<br/>Humans<br/>Immunoglobulins, Intravenous--adverse effects<br/>Immunologic Factors--adverse effects<br/>Immunosuppression Therapy--methods<br/>Kidney Transplantation--immunology<br/>Male<br/>Middle Aged<br/>Rituximab<br/>Survival Rate